vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and TIMBERLAND BANCORP INC (TSBK). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $21.7M, roughly 1.8× TIMBERLAND BANCORP INC). TIMBERLAND BANCORP INC runs the higher net margin — 37.8% vs -161.8%, a 199.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 10.4%). TIMBERLAND BANCORP INC produced more free cash flow last quarter ($5.6M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Timberland Bancorp Inc is a U.S.-based bank holding company operating primarily across Washington state. It provides a full range of personal and commercial banking services including checking and savings accounts, residential and commercial mortgages, small business loans, and wealth management solutions for local retail and small to mid-sized business clients.

IBRX vs TSBK — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.8× larger
IBRX
$38.3M
$21.7M
TSBK
Growing faster (revenue YoY)
IBRX
IBRX
+396.5% gap
IBRX
407.0%
10.4%
TSBK
Higher net margin
TSBK
TSBK
199.6% more per $
TSBK
37.8%
-161.8%
IBRX
More free cash flow
TSBK
TSBK
$76.9M more FCF
TSBK
$5.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
TSBK
TSBK
Revenue
$38.3M
$21.7M
Net Profit
$-61.9M
$8.2M
Gross Margin
99.0%
Operating Margin
-169.0%
Net Margin
-161.8%
37.8%
Revenue YoY
407.0%
10.4%
Net Profit YoY
-4.7%
19.8%
EPS (diluted)
$-0.06
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
TSBK
TSBK
Q4 25
$38.3M
$21.7M
Q3 25
$32.1M
$22.5M
Q2 25
$26.4M
$20.5M
Q1 25
$16.5M
$19.9M
Q4 24
$7.6M
$19.7M
Q3 24
$6.1M
$19.5M
Q2 24
$18.8M
Q1 24
$18.3M
Net Profit
IBRX
IBRX
TSBK
TSBK
Q4 25
$-61.9M
$8.2M
Q3 25
$-67.3M
$8.4M
Q2 25
$-92.6M
$7.1M
Q1 25
$-129.6M
$6.8M
Q4 24
$-59.2M
$6.9M
Q3 24
$-85.7M
$6.4M
Q2 24
$5.9M
Q1 24
$5.7M
Gross Margin
IBRX
IBRX
TSBK
TSBK
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
TSBK
TSBK
Q4 25
-169.0%
Q3 25
-173.5%
Q2 25
-269.8%
Q1 25
-390.1%
Q4 24
-919.0%
Q3 24
-1314.3%
Q2 24
Q1 24
Net Margin
IBRX
IBRX
TSBK
TSBK
Q4 25
-161.8%
37.8%
Q3 25
-209.8%
37.6%
Q2 25
-350.3%
34.6%
Q1 25
-784.9%
33.9%
Q4 24
-783.4%
34.9%
Q3 24
-1404.0%
32.6%
Q2 24
31.6%
Q1 24
31.3%
EPS (diluted)
IBRX
IBRX
TSBK
TSBK
Q4 25
$-0.06
$1.04
Q3 25
$-0.07
$1.06
Q2 25
$-0.10
$0.90
Q1 25
$-0.15
$0.85
Q4 24
$-0.08
$0.86
Q3 24
$-0.14
$0.80
Q2 24
$0.74
Q1 24
$0.70

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
TSBK
TSBK
Cash + ST InvestmentsLiquidity on hand
$242.8M
$246.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$268.4M
Total Assets
$501.9M
$2.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
TSBK
TSBK
Q4 25
$242.8M
$246.9M
Q3 25
$257.8M
$243.4M
Q2 25
$153.7M
$193.6M
Q1 25
$61.6M
$191.2M
Q4 24
$149.8M
$164.1M
Q3 24
$130.4M
$164.7M
Q2 24
$158.9M
Q1 24
$180.3M
Stockholders' Equity
IBRX
IBRX
TSBK
TSBK
Q4 25
$-500.5M
$268.4M
Q3 25
$-524.3M
$262.6M
Q2 25
$-570.7M
$256.7M
Q1 25
$-591.4M
$252.5M
Q4 24
$-489.1M
$249.2M
Q3 24
$-745.1M
$245.4M
Q2 24
$241.2M
Q1 24
$238.7M
Total Assets
IBRX
IBRX
TSBK
TSBK
Q4 25
$501.9M
$2.0B
Q3 25
$519.0M
$2.0B
Q2 25
$402.1M
$2.0B
Q1 25
$303.8M
$1.9B
Q4 24
$382.9M
$1.9B
Q3 24
$364.6M
$1.9B
Q2 24
$1.9B
Q1 24
$1.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
TSBK
TSBK
Operating Cash FlowLast quarter
$-70.4M
$6.1M
Free Cash FlowOCF − Capex
$-71.3M
$5.6M
FCF MarginFCF / Revenue
-186.2%
25.7%
Capex IntensityCapex / Revenue
2.4%
2.3%
Cash ConversionOCF / Net Profit
0.74×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$56.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
TSBK
TSBK
Q4 25
$-70.4M
$6.1M
Q3 25
$-68.9M
$30.2M
Q2 25
$-79.7M
$10.8M
Q1 25
$-85.9M
$12.4M
Q4 24
$-85.1M
$-3.1M
Q3 24
$-98.8M
$23.0M
Q2 24
$7.4M
Q1 24
$4.1M
Free Cash Flow
IBRX
IBRX
TSBK
TSBK
Q4 25
$-71.3M
$5.6M
Q3 25
$-69.6M
$28.4M
Q2 25
$-80.8M
$10.3M
Q1 25
$-87.0M
$12.2M
Q4 24
$-87.3M
$-3.6M
Q3 24
$-101.6M
$21.7M
Q2 24
$7.2M
Q1 24
$3.6M
FCF Margin
IBRX
IBRX
TSBK
TSBK
Q4 25
-186.2%
25.7%
Q3 25
-217.2%
126.4%
Q2 25
-305.9%
50.5%
Q1 25
-526.9%
61.1%
Q4 24
-1155.4%
-18.1%
Q3 24
-1663.2%
111.5%
Q2 24
38.4%
Q1 24
19.8%
Capex Intensity
IBRX
IBRX
TSBK
TSBK
Q4 25
2.4%
2.3%
Q3 25
2.3%
7.7%
Q2 25
4.1%
2.1%
Q1 25
6.8%
1.0%
Q4 24
28.0%
2.6%
Q3 24
45.7%
6.7%
Q2 24
1.1%
Q1 24
2.7%
Cash Conversion
IBRX
IBRX
TSBK
TSBK
Q4 25
0.74×
Q3 25
3.57×
Q2 25
1.52×
Q1 25
1.83×
Q4 24
-0.45×
Q3 24
3.62×
Q2 24
1.25×
Q1 24
0.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons